← Back to patent-cliff list
Relutrigine
Tier C — Watch / tradeRelutrigine
Praxis Precision Medicines
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Nav1.6
Indications (approved)：发育性和癫痫性脑病, 脑疾病, Epilepsy
Regional status
US
Phase III
2023-08-02
EU
Phase III
2023-08-02
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Relutrigine?
Approved indications include: 发育性和癫痫性脑病, 脑疾病, Epilepsy.
When does the Relutrigine patent expire?
No public expiry year is available for Relutrigine yet; this page updates once verified.
How do I get a quote for Relutrigine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02